Navigation Links
Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
Date:10/8/2008

Company Announces Corporate Restructuring to Focus on Strategic Alliances

and M&A

SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN), a company developing innovative therapeutics for the treatment of viral infections and cancer, today provided an update on its ongoing development programs. The company also announced that it will initiate a corporate restructuring that will extend the company's financial resources to pursue near-term corporate development opportunities, sale of specific programs, M&A and alternative financial arrangements to maximize the value of its assets.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

"We are committed to the continued advancement of HspE7, Hsp 6/11 and Poly-ICR, and as such, we are making difficult yet necessary decisions today to ensure these products have every opportunity to succeed," said Gregory M. McKee, president and chief executive officer at Nventa. "As part of our commitment to the continued advancement of HspE7, Hsp 6/11 and Poly-ICR, we are aggressively seeking strategic alliances, including merger and acquisition opportunities, which will allow us to realize the greatest value for each of these important programs."

HspE7: Lead Product Candidate for the Treatment of Cervical Intraepithelial Neoplasia (CIN)

A recently completed Phase 1 clinical trial of HspE7, a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), demonstrated an excellent safety profile, while providing compelling data to support HspE7's immunologic activity. Based on the positive Phase 1 trial results, the next planned initiatives include Phase 2 clinical studies that will evaluate HspE7 as a potential treatment for both low-grade cervical dysplasia (CIN 1
'/>"/>

SOURCE Nventa Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. CardioDynamics Provides 2007 Shareholder Meeting Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  The In Silico ... that will be featured at the conference, which takes ... on December 3 and 4, 2014. Researchers, students, drug ... to hear the following: KEYNOTE SPEAKERS ... Diego Skaggs School of Pharmacy Drug ...
(Date:9/17/2014)... San Jose, California (PRWEB) September 17, 2014 ... disintegrated by naturally occurring microorganisms such as bacteria, ... subsequently transformed into water, methane, biomass, inorganic compounds, ... With enhanced processability, expanding customer base and improved ... environmentally beneficial and economically viable alternative to conventional ...
(Date:9/17/2014)... 2014 Terracon Corporation has announced the ... tank . This addition to the company’s industry-leading ... linear polyethylene and available in 125 or 250 gallon ... in two weeks or less. , The new pre-engineered ... in Terracon’s existing TerraPure tank line – plus quick ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... develops and commercializes proprietary technologies and products for advanced ... been approved for trading in the United ... is expected to commence on September 17, 2014 on ... continue to trade on the TSX Venture Exchange under ...
Breaking Biology Technology:In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3
... Corporation,(Nasdaq: PARS ) announced today that it ... of its 10% Convertible Debentures due November 2012. ... amount of the,Debentures, at par, and received gross ... consisted of certain existing investors in the Company,namely ...
... Clinical and Commercial Adoption of the ... Axxent(R) Electronic Brachytherapy System, FREMONT, Calif., ... Brachytherapy System, a proprietary cancer treatment,platform that utilizes X-rays ... today announced that it will,present at the 26th Annual ...
... Cascades Technologies, Inc. (CTi),an 8(a) federal government ... it has been awarded a five-year, $3.5 ... USA.gov, the U.S.,government,s official web portal. CTi ... usability assistance,optimization services and project management support ...
Cached Biology Technology:Pharmos Corporation Completes Initial Closing of Private Placement 2Xoft to Present at the 26th Annual JPMorgan Healthcare Conference 2GSA Selects Cascades Technologies, Inc. (CTi) to Support USA.gov 2
(Date:9/18/2014)... Sticklebacks, the roaches of the fish world, are the ... control body shape. They,ve moved from the ocean into ... the world, each time changing their skeleton to adapt ... and freshwater populations of sticklebacks now have turned up ... evidence that a simple change in that gene,s regulation ...
(Date:9/17/2014)... instrumental in the creation of the Santa Ana Wildfire ... fire threat potential of the powerful, hot, dry Santa ... inferno. The index was introduced Sept. 17 by the ... Diego Gas and Electric. , The index includes four ... be used to help fire agencies and other emergency ...
(Date:9/17/2014)... Washington, USA -- "Nature has developed, very cleverly, some ... desire in optical design," said Joseph Shaw, director of ... we explore surfaces and structures at the nanoscale, we,ll ... in San Diego in August during a conference called ... Shaw and Rongguang Liang of the University of Arizona ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3
... R.I. [Brown University] In a new study in ... out in unprecedented detail a neurological signaling breakdown in ... each year, characterized by developmental delay, seizures, and other ... a synthesized, peptide-like compound called CN2097 works to restore ...
... still get through security with explosives on their person? ... Chemical and Materials Engineering has revealed a new way ... A team of researchers including post-doctoral fellows Seonghwan ... Charles Van Neste, visiting professor, Sangmin Jeon from the ...
... announced a change to current dosages for sleeping medications ... research suggests that flu dosages for women be reconsidered ... should be common practice, but we aren,t there yet. ... into medical education and clinical training, the Sex and ...
Cached Biology News:Study in mice yields Angelman advance 2Study in mice yields Angelman advance 3Study in mice yields Angelman advance 4Explosive breakthrough in research on molecular recognition 2Sex and gender competency essential to medical care 2
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... working in a regulated environment, Pipette ... calibration software that automates gravimetric pipette ... framework that meets todays regulatory compliance ... secure solution that includes a full ...
... of the yolk protein Vtg in plasma from ... sensitive biomarker for endocrine disrupting chemicals (EDCs) with ... become an accepted screening test for the estrogenic ... trout) EIA kit is a double-antibody immunometric (sandwich) ...
... (RTL) can provide you with the ... method development and validation ,Performance of ... of your GMP manufacturing environment ,Assurance ... a full spectrum of microbiological services ...
Biology Products: